ArticleCancer medicine2026
Impact of Dyslipidemia on Clinical Outcomes Among Cancer Patients Treated With Immune Checkpoint Inhibitors.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
This study aimed to investigate the influence of baseline blood lipid profiles on therapeutic efficacy and adverse events (AEs) among cancer patients treated with immune checkpoint inhibitors (ICIs). We retrospectively analyzed patients with solid tumors who received ICIs, with a focus on their blood lipid profiles at baseline. Associations between dyslipidemia and clinical outcomes following ICI therapy were assessed using both univariate and multivariable analyses. A total of 99 eligible patients were included: 52 with renal cell carcinoma, 23 with urothelial carcinoma, and 24 with esophageal carcinoma. Among patients with renal cell carcinoma, low-density lipoprotein (LDL) cholesterol ≥ 140 mg/dL (p = 0.013) and high-density lipoprotein (HDL) cholesterol ≤ 40 mg/dL (p = 0.040) were significantly associated with shorter overall survival. Conversely, among patients with esophageal carcinoma, LDL cholesterol ≥ 120 mg/dL was associated with longer progression-free survival (p = 0.035). Among all patients, HDL cholesterol < 40 mg/dL was identified as a risk factor for Grade 3 or higher AEs (p = 0.018), especially liver injury (p = 0.033). Prior statin use was associated with a trend toward an improved response to ICIs among patients with renal cell carcinoma (p = 0.057). Baseline blood lipid profiles-particularly LDL and HDL cholesterol levels-may influence clinical outcomes among cancer patients receiving ICI therapy. These findings suggest that lipid profiles might serve as predictive biomarkers for the efficacy and safety of ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.